Innovative Testing Laboratory Offers Accurate Solution to Aid in Effective ADHD Treatment
Harmonyx, a leading company in affordable and accessible genetic testing, has launched a new test for guided prescription therapy for Attention Deficit Hyperactivity Disorder (ADHD). The first-of-its-kind offering places power in patients’ hands by providing them with information regarding whether a medication will work for them or not. The test also allows physicians and pharmacists to make informed decisions about which medication will be most effective for their patients.
According to a recent study published by the Centers for Disease Control and Prevention and the Health Resources and Services Administration, ADHD is one of the most common neurodevelopmental disorders among children.
Using data from the 2003 and 2007 National Survey of Children’s Health reflect the increasing prevalence of parent-reported attention-deficit/hyperactivity disorder (ADHD) diagnosis and treatment by health care providers.
Among the results the researchers found prevalence of medicated ADHD increased by 11 percent from 2007 to 2011. In 2011, approximately two million more US children/adolescents aged 4 to 17 years had been diagnosed with ADHD and more than two- thirds of those with current ADHD were taking medication for treatment
One in five high school boys and one in 11 high school girls currently live with an ADHD diagnosis. And, more than 4 percent of adults in the United States live with ADHD.
At less than $100, The Harmonyx® Test for ADHD helps bridge the gap in therapeutic outcomes between patients who respond well to initial therapies and those who do not. The test is ideal for patients with new or recent ADHD diagnoses, patients currently undergoing ineffective ADHD treatment and those interested in a stimulant alternative.
“We are seeing all too often a trial-and-error approach to the prescription process,” said Bob Bean, President and CEO of Harmonyx. “This is a slow and inadequate way to help those diagnosed with ADHD get the effective treatment they need. Our affordable new test gives caregivers, parents and patients the ability to make informed decisions about the medications they choose.”
With a simple swab test that can be purchased from a pharmacy, the ADHD test examines the effects of four genes on the patient’s metabolism and efficacy of 21 ADHD medications, such as Adderall®, Vyvanse®, Ritalin®, Strattera® and Dexedrine®, among others. Detailed results that provide clear guidance to ADHD therapy are returned to the pharmacist and treating physician in as little as 24 hours once the laboratory receives the test.
Harmonyx offers testing for three classes of medication – Antiplatelets (Plavix® / clopidogrel), Statins (Zocor® / simvastatin) and ADHD. To learn more about Harmonyx or to find a Harmonyx pharmacy in your area, visit http://www.harmonyxdiagnostics.com.
Harmonyx Diagnostics is an innovative Memphis-based company that is changing the way medicine is prescribed in America. Founded in 2009, Harmonyx believes patients should have the power to pay for affordable genetic testing without the hurdles health insurance can cause. Harmonyx uses a fully automated genotyping system to deliver fast, easy and accurate results to qualified healthcare professionals, helping them determine the appropriate medication and dosing for each patient. Harmonyx is CAP accredited and CLIA-certified automated genetic testing laboratory. For more information, visit www.harmonyxdiagnostics.com.